Treatment Options in Metastatic Castration-Resistant Prostate Cancer

In this K-Cast video series, Neal Shore, MD, describes current standards in the treatment of metastatic castration-resistant prostate cancer (mCRPC) and provides an overview of data from the PROfound trial. Also discussed are genetic testing in mCRPC, the impact of coronavirus disease 2019 on patient care, the role of PARP inhibitors in patients with mCRPC, and considerations for the management of mCRPC.